Using capsaicin patches to treat painful hand osteoarthritis
Official title: Capsaicin in Digital Osteoarthritis Versus Control : a Randomized Study
Run by University Hospital, Clermont-Ferrand · NCT06444919 · Data updated 2026-11-12
This study is testing if a stronger capsaicin patch can help people with painful hand osteoarthritis feel less pain compared to a weaker version.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 4 sites (Clermont-Ferrand and 3 other locations) |
| Status | Recruiting |
| Started | March 7, 2025 |
| Main results expected | January 1, 2028 |
| Study ends | January 1, 2028 |
| Registry record updated | March 13, 2025 |
| Trial ID | NCT06444919 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with digital osteoarthritis who experience significant finger pain and have a neuropathic pain component.
✕Probably not a fit
Patients with isolated rhizarthrosis or other joint diseases affecting the fingers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicentric, randomized controlled double-blind clinical trial aims to evaluate the efficacy of a transdermal capsaicin patch (8%) compared to a lower dose (0.04%) in patients suffering from painful digital osteoarthritis with a neuropathic pain component. Participants will be randomly assigned to receive either the higher concentration capsaicin patch or the control patch, and their pain levels will be assessed at 60 days. The study will also involve monitoring the use of analgesics and measuring inflammatory markers through blood samples. The goal is to determine if the higher dose of capsaicin can significantly reduce pain compared to the lower dose.
Why it matters
Potential benefit: If successful, this treatment could provide significant pain relief for patients with digital osteoarthritis and neuropathic pain.
How similar studies have gone: Other studies have shown promise in using capsaicin for pain relief, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of digital osteoarthritis fulfilling the American College of Rheumatology criteria; * Presence of finger pain of ≥ 40 mm on a visual analogue scale (VAS); * Presence of finger pain with a neuropathic pain component (DN4 score ≥ 4/10) * Inadequate response, adverse reactions, and/or contraindications to conventional analgesics and NSAIDs; Exclusion Criteria: * Patient with isolated rhizarthrosis; * Patient with other joint disease affecting the fingers (gout, chondrocalcinosis, RA, spondyloarthritis, psoriatic arthritis); * Patient with upper extremity pain syndrome that may interfere with the assessment of finger pain; * Patient with another pathology responsible for neuropathic hand pain (carpal tunnel syndrome, diabetic neuropathy, Guyon's tunnel syndrome, cervicobrachial neuralgia, brachial plexitis); * Patient with skin lesions on the fingers (psoriasis, wounds, chronic ulcers, eczema, shingles, dermatitis); * Patient with poorly controlled high blood pressure; * Patient with hypersensitivity to capsaicin; * Patient who had 8% capsaicin patch use in the year prior to the study; * Patient who has received intramuscular, intra-articular or intravenous corticosteroid therapy, another disease-modifying anti-rheumatic therapy (methotrexate, salazopyrine) or an intra-articular injection into the joints of the fingers within the previous 3 months; * Patient wearing wrist or finger orthoses in the previous month; * Patient with fibromyalgia;
Where it's running
-
CHU de Clermont-Ferrand
Clermont-Ferrand, France Recruiting -
HCL Hôpital Edouard Herriot
Lyon, France Recruiting -
AP-HP Hôpital Saint-Antoine
Paris, France Recruiting -
CHU de Saint-Etienne
Saint-Etienne, France Recruiting
Study contacts
- Principal investigator: Sylvain Mathieu — University Hospital, Clermont-Ferrand
- Study coordinator: Lise Laclautre
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: 334.73.754.963
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Neuropathic Pain Severity in Lumbar Spinal Stenosis and Its Link to Radiology
This study will test how severe neuropathic pain is in adults with lumbar spinal stenosis and see if it relates to MRI findings and other clinical features.
-
Virtual Reality-Based Hypnotherapy to Help Pain, Sleep, and Mood in Spinal Cord Injury
Adults with spinal cord injury will try adding short VR-based hypnotherapy sessions to their standard physiotherapy to see if it reduces pain and improves sleep and mood.
-
Extended-release Pregabalin for nerve pain from diabetes or shingles
This phase 3 study tests an extended-release form of pregabalin to see if it reduces nerve-pain symptoms in adults with diabetic neuropathy or postherpetic neuralgia.
-
High-Intensity Peripheral Magnetic Stimulation for Traumatic Nerve Injury
This study tests whether adding high-intensity peripheral magnetic stimulation to a structured exercise program can reduce pain and improve function for adults with a traumatic peripheral nerve injury.
-
Hematological clues and how patients respond to nerve blocks for neuropathic pain
This study looks at blood inflammation markers to see if they relate to how well people with neuropathic pain respond to sympathetic nerve blocks.
-
Cord plasma eye drops to treat neuropathic corneal pain
This trial will test whether cord plasma eye drops can reduce long-lasting nerve-related corneal pain in people with evidence of corneal nerve damage.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.